Abstract
Opsoclonus–myoclonus syndrome in adults is a rare and heterogeneous disorder with the clinical features of opsoclonus, myoclonus, ataxia, and behavioral and sleep disturbances. The pathophysiology is thought to be immunological on the basis of paraneoplastic or infectious etiologies. Immunomodulatory therapies should be performed although the response may be incomplete. A number of autoantibodies have been identified against a variety of antigens, but no diagnostic immunological marker has yet been identified. This review focuses on underlying mechanisms of opsoclonus–myoclonus syndrome, including findings that have been identified recently, and provides an update on the clinical features and treatments of this condition.
Similar content being viewed by others
References
Leigh RJ, Zee DS. The neurology of eye movements [online]. Print ISBN-13: 9780199969289. Published online: Jun 2015. https://doi.org/10.1093/med/9780199969289.001.0001
Pang KK, de Sousa C, Lang B, Pike MG (2010) A prospective study of the presentation and management of dancing eye syndrome/opsoclonus–myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 14:156–161
Rothenberg AB, Berdon WE, D’Angio GJ, Yamashiro DJ, Cowles RA (2009) The association between neuroblastoma and opsoclonus–myoclonus syndrome: a historical review. Pediatr Radiol 39:723–726
Luque FA, Furneaux HM, Ferziger R et al (1991) Anti-Ri—an antibody associated with paraneoplastic opsoclonus and breast-cancer. Ann Neurol 29:241–251
Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NKV, Dalmau J (2003) Autoantigen diversity in the opsoclonus–myoclonus syndrome. Ann Neurol 53:347–353
Armangue T, Sabater L, Torres-Vega E et al (2016) Clinical and immunological features of opsoclonus–myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 73:417–424
Herman TE, Siegel MJ (2009) Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr 48:336–340
Krug P, Schleiermacher G, Michon J et al (2010) Opsoclonus–myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 14:400–409
Digre KB (1986) Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 43:1165–1175
Whiteley AM, Swash M, Urich H (1976) Progressive encephalomyelitis with rigidity. Brain 99:27–42
McKeon A, Pittock SJ, Glass GA et al (2007) Whole-body tremulousness: isolated generalized polymyoclonus. Arch Neurol 64:1318–1322
Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ (2005) Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus–myoclonus syndrome. J Pediatr Oncol Nurs 22:8–19
De Grandis E, Parodi S, Conte M et al (2009) Long-term follow-up of neuroblastoma-associated opsoclonus–myoclonus-ataxia syndrome. Neuropediatrics 40:103–111
Matthay KK, Blaes F, Hero B et al (2005) Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 228:275–282
Pranzatelli MR (1996) The immunopharmacology of the opsoclonus–myoclonus syndrome. Clin Neuropharmacol 19:1–47
Anderson NE, Buddesteffen C, Rosenblum MK et al (1988) Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer—a distinct para-neoplastic syndrome. Medicine 67:100–109
Antunes NL, Khakoo Y, Matthay KK et al (2000) Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus–myoclonus. J Pediatr Hematol Oncol 22:315–320
Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937
Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J (2001) Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50:339–348
Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA (2001) Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189:71–81
Kurian M, Lalive PH, Dalmau JO, Horvath J (2010) Opsoclonus–myoclonus syndrome in anti-N-methyl-d-aspartate receptor encephalitis. Arch Neurol 67:118–121
Saiz A, Dalmau J, Butler MH et al (1999) Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 66:214–217
Bataller L, Graus F, Saiz A, Vilchez JJ, Spanish Opsoclonus–myoclonus Study G (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124:437–443
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–154
Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J (2003) Autoantigen diversity in the opsoclonus–myoclonus syndrome. Ann Neurol 53:347–353
Noetzel MJ, Cawley LP, James VL, Minard BJ, Agrawal HC (1987) Anti-neurofilament protein antibodies in opsoclonus–myoclonus. J Neuroimmunol 15:137–145
Dropcho EJ, Kline LB, Riser J (1993) Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus–myoclonus. Neurology 43:207–211
Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53:580–587
Bataller L, Graus F, Saiz A, Vilchez JJ, Study SOM (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124:437–443
Scholz J, Vieregge P, Ruff C (1994) Paraneoplastic opsoclonus–myoclonus syndrome in metastatic ovarian-carcinoma. J Neurol Neurosur Ps 57:763–764
Caviness JN, Forsyth PA, Layton DD, Mcphee TJ (1995) The movement disorder of adult opsoclonus. Mov Disord 10:22–27
Jongen JLM, Moll WJB, Smitt PAES, Vecht CJ, Tijssen CC (1998) Anti-Ri positive opsoclonus–myoclonus-ataxia in ovarian duct cancer. J Neurol 245:691–692
Moretti R, Torre P, Antonello RM, Nasuelli D, Cazzato G (2000) Opsoclonus–myoclonus syndrome: gabapentin as a new therapeutic proposal. Eur J Neurol 7:455–456
Lou E, Hensley ML, Lassman AB, Aghajanian C (2010) Paraneoplastic opsoclonus–myoclonus syndrome secondary to immature ovarian teratoma. Gynecol Oncol 117:382–384
De Luca S, Terrone C, Crivellaro S et al (2002) Opsoclonus–myoclonus syndrome as a paraneoplastic manifestation of renal cell carcinoma—a case report and review of the literature. Urol Int 68:206–208
Kumar A, Lajara-Nanson WA, Neilson RW (2005) Paraneoplastic opsoclonus–myoclonus syndrome: initial presentation of non-Hodgkins lymphoma. J Neuro Oncol 73:43–45
Berger JR, Mehari E (1999) Paraneoplastic opsoclonus–myoclonus secondary to malignant melanoma. J Neuro Oncol 41:43–45
Jung KY, Youn J, Chung CS (2006) Opsoclonus–myoclonus syndrome in an adult with malignant melanoma. J Neurol 253:942–943
Blaes F, Pike MG, Lang B (2008) Autoantibodies in childhood opsoclonus–myoclonus syndrome. J Neuroimmunol 201:221–226
Klaas JP, Ahlskog JE, Pittock SJ et al (2012) Adult-onset opsoclonus–myoclonus syndrome. Arch Neurol 69:1598–1607
Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY (1994) Paraneoplastic opsoclonus–myoclonus associated with anti-Hu antibody. Neurology 44:1754–1755
Smith JH, Dhamija R, Moseley BD et al (2011) N-Methyl-d-aspartate receptor autoimmune encephalitis presenting with opsoclonus–myoclonus treatment response to plasmapheresis. Arch Neurol-Chicago 68:1069–1072
Josephson CB, Grant I, Benstead T (2009) Opsoclonus–myoclonus with multiple paraneoplastic syndromes and VGCC antibodies. Can J Neurol Sci 36:512–514
Simister RJ, Ng K, Lang B, Beckles M, Chao D, McCabe DJH (2011) Sequential fluctuating paraneoplastic ocular flutter-opsoclonus–myoclonus syndrome and Lambert-Eaton myasthenic syndrome in small-cell lung cancer. J Neurol Neurosur Ps 82:344–346
Dalakas MC (2008) Invited article: inhibition of B cell functions—implications for neurology. Neurology 70:2252–2260
Pranzatelli MR, Travelstead AL, Tate ED et al (2004) B- and T-cell markers in opsoclonus–myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 62:1526–1532
Pranzatelli MR, Tate ED, McGee NR et al (2013) BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflamm 10:10
Raffaghello L, Conte M, De Grandis E, Pistoia V (2009) Immunological mechanisms in opsoclonus–myoclonus associated neuroblastoma. EJPN 13:219–223
Fuhlhuber V, Altenkamper S, Bick S et al (2008) Serum and cerebrospinal fluid levels of the B-cell activating factor BAFF in paediatric opsoclonus–myoclonus syndrome—correlation with neuronal surface-binding autoantibodies. J Neurol 255:54–54
Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA (2008) Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus–myoclonus syndrome. Cytokine 44:26–32
Wong A (2007) An update on opsoclonus. Curr Opin Neurol 20:25–31
Scott KM, Parker F, Heckmann JM (2009) Opsoclonus–myoclonus syndrome and HIV-infection. J Neurol Sci 284:192–195
Huber BM, Strozzi S, Steinlin M, Aebi C, Fluri S (2010) Mycoplasma pneumoniae associated opsoclonus–myoclonus syndrome in three cases. Eur J Pediatr 169:441–445
Flabeau O, Meissner W, Foubert-Samier A, Guehl D, Desbordes P, Tison F (2009) Opsoclonus myoclonus syndrome in the context of Salmonellosis. Mov Disord 24:2306–2308
Zaganas I, Prinianakis G, Xirouchaki N, Mavridis M (2007) Opsoclonus–myoclonus syndrome associated with cytomegalovirus encephalitis. Neurology 68:1636
Crawford JR, Kadom N, Santi MR, Mariani B, Lavenstein BL (2007) Human herpesvirus 6 rhombencephalitis in immunocompetent children. J Child Neurol 22:1260–1268
Ertekin V, Tan H (2010) Opsoclonus–myoclonus Syndrome Attributable to Hepatitis C Infection. Pediatr Neurol 42:441–442
Ayarza A, Parisi V, Altclas J et al (2009) Opsoclonus–myoclonus-ataxia syndrome and HIV seroconversion. J Neurol 256:1024–1025
Kanjanasut N, Phanthumchinda K, Bhidayasiri R (2010) HIV-related opsoclonus–myoclonus-ataxia syndrome: report on two cases. Clin Neurol Neurosurg 112:572–574
Armangue T, Leypoldt F, Malaga I et al (2014) Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75:317–323
Verma A, Brozman B (2002) Opsoclonus–myoclonus syndrome following Epstein-Barr virus infection. Neurology 58:1131–1132
Khosla JS, Edelman MJ, Kennedy N, Reich SG (2005) West Nile virus presenting as opsoclonus–myoclonus cerebellar ataxia. Neurology 64:1095–1095
Krasenbrink I, Fuhlhuber V, Juhasz-Boess I et al (2007) Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus–myoclonus syndrome (OMS). Neuropediatrics 38:114–116
Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A (2008) Opsoclonus–myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg 110:619–621
Cardoso F (2002) Chorea gravidarum. Arch Neurol-Chicago 59:868–870
Koide R, Sakamoto M, Tanaka K, Hayashi H (2004) Opsoclonus–myoclonus syndrome during pregnancy. J Neuro-Ophthalmol 24:273–273
Zee DS, Robinson DA (1979) A hypothetical explanation of saccadic oscillations. Ann Neurol 5:405–414
Ridley A, Kennard C, Scholtz CL, Buttner-Ennever JA, Summers B, Turnbull A (1987) Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 110(Pt 6):1699–1709
Ashe J, Hain TC, Zee DS, Schatz NJ (1991) Microsaccadic flutter. Brain 114(Pt 1B):461–472
Bhidayasiri R, Somers JT, Kim JI et al (2001) Ocular oscillations induced by shifts of the direction and depth of visual fixation. Ann Neurol 49:24–28
Shaikh AG, Ramat S, Optican LM, Miura K, Leigh RJ, Zee DS (2008) Saccadic burst cell membrane dysfunction is responsible for saccadic oscillations. J Neuroophthalmol 28:329–336
Ramat S, Leigh RJ, Zee DS, Optican LM (2005) Ocular oscillations generated by coupling of brainstem excitatory and inhibitory saccadic burst neurons. Exp Brain Res 160:89–106
Ramat S, Leigh RJ, Zee DS, Optican LM (2007) What clinical disorders tell us about the neural control of saccadic eye movements. Brain 130:10–35
Helmchen C, Rambold H, Sprenger A, Erdmann C, Binkofski F (2003) f MRIs. Cerebellar activation in opsoclonus: an fMRI study. Neurology 61:412–415
van Toorn R, Rabie H, Warwick JM (2005) Opsoclonus–myoclonus in an HIV-infected child on antiretroviral therapy-possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol 9:423–426
Blumkin L, Kivity S, Lev D et al (2012) A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus–myoclonus ataxia-like syndrome. J Neurol 259:2590–2598
Oh SY, Boegle R, Eulenburg PZ, Ertl M, Kim JS, Dieterich M (2017) Longitudinal multi-modal neuroimaging in opsoclonus–myoclonus syndrome. J Neurol 264:512–519
Sperry RW (1950) Neural basis of the spontaneous optokinetic response produced by visual inversion. J Comp Physiol Psychol 43:482–489
Paus T, Marrett S, Worsley KJ, Evans AC (1995) Extraretinal modulation of cerebral blood flow in the human visual cortex: implications for saccadic suppression. J Neurophysiol 74:2179–2183
Burr DC, Morrone MC, Ross J (1994) Selective suppression of the magnocellular visual pathway during saccadic eye movements. Nature 371:511–513
Blaes F, Fuhlhuber V, Korfei M et al (2005) Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 58:313–317
Pranzatelli MR, Tate ED, Travelstead AL et al (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J Pediatr Hematol Oncol 28:585–593
Pranzatelli MR, Tate ED, Shenoy S, Travelstead AL (2012) Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus–myoclonus. Pediatr Blood Cancer 58:988–991
Rudnick E, Khakoo Y, Antunes NL et al (2001) Opsoclonus–myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children’s Cancer Group Study. Med Pediatr Oncol 36:612–622
Mitchell WG, Davalos-Gonzalez Y, Brumm VL et al (2002) Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 109:86–98
Hammer MS, Larsen MB, Stack CV (1995) Outcome of children with opsoclonus–myoclonus regardless of etiology. Pediatr Neurol 13:21–24
Rostasy K, Wilken B, Baumann M et al (2006) High dose pulsatile dexamethasone therapy in children with opsoclonus–myoclonus syndrome. Neuropediatrics 37:291–295
Ertle F, Behnisch W, Al Mulla NA et al (2008) Treatment of neuroblastoma-related opsoclonus–myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 50:683–687
Gorman MP (2010) Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus-ataxia syndrome. Curr Opin Pediatr 22:745–750
de Alarcon PA, Matthay KK, London WB et al (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc 2:25–34
Wilken B, Baumann M, Bien CG, Hero B, Rostasy K, Hanefeld F (2008) Chronic relapsing opsoclonus–myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 12:51–55
Pranzatelli MR, Tate ED, Galvan I, Wheeler A (2001) Controlled pilot study of piracetam for pediatric opsoclonus–myoclonus. Clin Neuropharmacol 24:352–357
Mitchell WG, Wooten AA, O’Neil SH, Rodriguez JG, Cruz RE, Wittern R (2015) Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol 30:976–982
Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen MLC, van Noesel MM, Hakvoort-Cammel FGAJ, van den Heuvel-Eibrink MM (2009) Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer 53:1048–1053
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors report no conflicts of interest.
Rights and permissions
About this article
Cite this article
Oh, SY., Kim, JS. & Dieterich, M. Update on opsoclonus–myoclonus syndrome in adults. J Neurol 266, 1541–1548 (2019). https://doi.org/10.1007/s00415-018-9138-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-9138-7